pyrroles has been researched along with Rhabdomyosarcoma in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Coarfa, C; Dasgupta, A; Kurenbekova, L; Landesman, Y; Patel, T; Rainusso, N; Rajapakse, K; Shuck, RL; Sierra, L; Tsang, SV; Unger, T; Yustein, JT | 1 |
| Cassinelli, G; Cominetti, D; Favini, E; Lanzi, C; Penco, S; Petrangolini, G; Pisano, C; Tortoreto, M; Vlodavsky, I; Zaffaroni, N; Zunino, F | 1 |
| Boichuk, S; Dunaev, P; Galembikova, A; Khaibullina, S; Khusnutdinov, R; Lombardi, V; Ramazanov, B; Zykova, S | 1 |
| Ames, RY; Brannigan, BW; Erlander, MG; Greninger, P; Haber, DA; Iafrate, AJ; Lee, DY; Lucien, L; Ma, XJ; Maheswaran, S; McCutcheon, K; McDermott, U; Milano, R; Settleman, J; Sharma, SV; Stubbs, H; Tam, A; Ulkus, LE | 1 |
| Abraham, J; Efstratiadis, A; Giles, FG; Keller, C; Kilcoyne, A; LeGallo, RD; Malempati, S; McCleish, AT; Nelon, LD; Nishijo, K; Nowak, BM; Prajapati, SI; Rubin, BP; Schaffer, BS; Taniguchi, E | 1 |
| Bucci, F; Cassinelli, G; Cominetti, D; De Cesare, M; Di Francesco, AM; Lanzi, C; Meco, D; Orlandi, A; Passeri, D; Petrangolini, G; Pisano, C; Riccardi, R; Tortoreto, M; Zaffaroni, N; Zuco, V; Zunino, F | 1 |
| Benini, S; Croci, S; García-Echeverría, C; Hofmann, F; Lollini, PL; Lukas, S; Manara, MC; Nicoletti, G; Perdichizzi, S; Picci, P; Scotlandi, K; Serra, M; Zambelli, D | 1 |
7 other study(ies) available for pyrroles and Rhabdomyosarcoma
| Article | Year |
|---|---|
Targeting PAK4 Inhibits Ras-Mediated Signaling and Multiple Oncogenic Pathways in High-Risk Rhabdomyosarcoma.
Topics: Acrylamides; Aminopyridines; Animals; Apoptosis; Biomarkers, Tumor; Cell Movement; Cell Proliferation; Child; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; p21-Activated Kinases; Pyrazoles; Pyrroles; ras Proteins; Rhabdomyosarcoma; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |
Antitumor efficacy of the heparanase inhibitor SST0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Cell Line, Tumor; Child; Drug Synergism; Female; Glucuronidase; Heparin; Humans; Indoles; Mice; Mice, Nude; Neoplasm Invasiveness; Neovascularization, Pathologic; Osteosarcoma; Pyrroles; Rhabdomyosarcoma; Sunitinib; Xenograft Model Antitumor Assays | 2013 |
Ethyl-2-amino-pyrrole-3-carboxylates are novel potent anticancer agents that affect tubulin polymerization, induce G2/M cell-cycle arrest, and effectively inhibit soft tissue cancer cell growth in vitro.
Topics: Antineoplastic Agents; Bone Neoplasms; Carboxylic Acids; Cell Death; Cell Growth Processes; Cell Line, Tumor; G2 Phase Cell Cycle Checkpoints; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Leiomyosarcoma; M Phase Cell Cycle Checkpoints; Osteosarcoma; Pyrroles; Rhabdomyosarcoma; Sarcoma; Sarcoma, Ewing; Tubulin; Tubulin Modulators | 2016 |
Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors.
Topics: Antibodies; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Gene Amplification; Gene Expression Profiling; Humans; Indoles; Ligands; Lung Neoplasms; Lymphokines; Platelet-Derived Growth Factor; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Rhabdomyosarcoma; RNA, Small Interfering; Sunitinib | 2009 |
Evasion mechanisms to Igf1r inhibition in rhabdomyosarcoma.
Topics: Animals; Apoptosis; Blotting, Western; Cell Cycle; Cell Proliferation; Child; Chorioallantoic Membrane; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Embryo, Mammalian; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mice; Phosphorylation; Pyrimidines; Pyrroles; Quail; Quinazolines; Receptor, ErbB-2; Receptor, IGF Type 1; Reverse Transcriptase Polymerase Chain Reaction; Rhabdomyosarcoma; RNA Interference; Tumor Burden; Tumor Cells, Cultured; Young Adult | 2011 |
The curative efficacy of namitecan (ST1968) in preclinical models of pediatric sarcoma is associated with antiangiogenic effects.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Chemokine CCL2; Chemokine CXCL16; Chemokines, CXC; DNA Topoisomerases, Type I; Female; Fibroblast Growth Factor 2; Humans; Indoles; Mice; Mice, Nude; Pyrroles; Receptors, Scavenger; Rhabdomyosarcoma; Sarcoma; Sunitinib; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2012 |
Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Osteosarcoma; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Rhabdomyosarcoma; Sarcoma; Sarcoma, Ewing; Signal Transduction; Vincristine | 2005 |